Contineum Therapeutics financials
$11.50−9.66%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$68.1M | -$50.9M |
| Net income | -$60.0M | -$42.3M |
| Net margin | — | — |
| Diluted EPS | $-2.17 | $-2.18 |
| EBITDA | -$67.7M | -$50.6M |
| Operating cash flow | -$55.3M | -$32.8M |
| Free cash flow | -$55.5M | -$33.4M |
| Diluted shares | 27.7M | 19.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $75.6M | $21.9M |
| Short-term investments | $187.3M | $182.8M |
| Total debt | $0.00 | $0.00 |
| Total assets | $276.6M | $212.8M |
| Total liabilities | $15.7M | $14.8M |
| Shareholders' equity | $261.0M | $198.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology